Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 15,649 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BCAA Clear all
Terminated Phase 2 Interventional Results available

A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF

NCT00208949
View directory record Official record
Conditions
Hematologic Diseases
Interventions
G-CSF, GM-CSF
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravesicular Abraxane for Treatment-Refractory Bladder Cancer

NCT00583349
View directory record Official record
Conditions
Bladder Cancer
Interventions
Abraxane
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 25, 2026, 7:06 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation

NCT06141447
View directory record Official record
Conditions
Hemorrhage
Interventions
Oxytocin + normal saline, Normal saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 25, 2026, 7:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

A 2-part Phase 1/2 Open-label Trial on ODM-212

NCT07563738
View directory record Official record
Conditions
Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

NCT03137407
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Botulinum Toxins, Type A, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Duluth, Georgia • Des Plaines, Illinois • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 25, 2026, 7:06 AM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

NCT00019864
View directory record Official record
Conditions
Cardiac Toxicity, Sarcoma
Interventions
filgrastim, cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, leucovorin calcium, methotrexate, adjuvant therapy, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
4
States / cities
Bethesda, Maryland • Oklahoma City, Oklahoma • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 25, 2026, 7:06 AM EDT
Withdrawn No phase listed Observational

Pharmacokinetics of Vancomycin in the ICU in Renal Replacement Therapy

NCT00848809
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Blood sample
Procedure
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 25, 2026, 7:06 AM EDT
Terminated Phase 3 Interventional

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

NCT00092287
View directory record Official record
Conditions
Malignant Carcinoid Syndrome
Interventions
lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 25, 2026, 7:06 AM EDT
Terminated Phase 1 Interventional

INNO-105 in Patients With Solid Tumors

NCT00255333
View directory record Official record
Conditions
Tumors
Interventions
INNO-105
Drug
Lead sponsor
Innovive Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2007 · Synced Oct 25, 2026, 7:06 AM EDT
Active, not recruiting Phase 2 Interventional

MTT for Children With ASD Who Have Gastrointestinal Disorders

NCT04182633
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
vancomycin, Miralax, intestinal microbiota, placebo vancomycin, Miralax, placebo intestinal microbiota
Combination Product
Lead sponsor
Arizona State University
Other
Eligibility
5 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 2 Interventional Results available

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

NCT00968071
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine, Gemtuzumab Ozogamicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

NCT03302234
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Ipilimumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Burbank, California • Monterey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

NCT00402909
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Nateglinide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
28 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 1 Interventional

Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection

NCT00001763
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Mycobacterium Avium-Intracellulare Infection
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 1 Interventional

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

NCT02546284
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia (CMML)
Interventions
lenzilumab
Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Tampa, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 25, 2026, 7:06 AM EDT
Terminated Phase 3 Interventional Results available

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery

NCT01086852
View directory record Official record
Conditions
Factor X Deficiency
Interventions
FACTOR X
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

NCT00890552
View directory record Official record
Conditions
Leukemia, Amyloidosis
Interventions
Lenalidomide, Melphalan, Dexamethasone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 2 Interventional

Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

NCT02462252
View directory record Official record
Conditions
Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome
Interventions
BL-8040, horse anti-thymocyte globulin (hATG), Methylprednisolone, Cyclosporine
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 2 Interventional

Chemotherapy Toxicity Reduction Via Urea Cycle Support

NCT00223730
View directory record Official record
Conditions
Cancer
Interventions
Citrulline, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 2 Interventional Results available

CAndesartan vs LIsinopril Effects on the BRain

NCT01984164
View directory record Official record
Conditions
Hypertension, Mild Cognitive Impairment
Interventions
Candesartan, Lisinopril
Drug
Lead sponsor
Emory University
Other
Eligibility
55 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 25, 2026, 7:06 AM EDT
Not listed Phase 1 Interventional

Understanding GWI: Integrative Modeling

NCT04255498
View directory record Official record
Conditions
Gulf War Illness, Persian Gulf Syndrome, Occupational Diseases
Interventions
Etanercept, Mifepristone
Drug
Lead sponsor
South Florida Veterans Affairs Foundation for Research and Education
Federal
Eligibility
40 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 25, 2026, 7:06 AM EDT
Completed Phase 4 Interventional Results available

RESTART C0168Z05 Rheumatoid Arthritis Study

NCT00714493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab
Biological
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 25, 2026, 7:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

NCT03033914
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 25, 2026, 7:06 AM EDT
Terminated Phase 1 Interventional

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

NCT02070406
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis
Drug · Biological · Radiation + 2 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 25, 2026, 7:06 AM EDT